Recruitment status changed
Before: Active not recruiting. After: Terminated.
Among the trials TrialRedline tracks, 90 changed their ClinicalTrials.gov record in April 2026: 4 status changes to terminated, withdrawn or suspended, 19 primary outcome text edits, 27 completion dates moved later, 2 completion dates moved earlier, 25 enrollment changes, 43 other status changes. Each entry shows the previous and updated value and links to the registry's own version comparison.
4 in April 2026. Recruitment status changed to Terminated, Withdrawn or Suspended. Terminated first, then newest.
Before: Active not recruiting. After: Terminated.
Before: Active not recruiting. After: Terminated.
Before: Recruiting. After: Terminated.
Before: Not yet recruiting. After: Suspended.
19 in April 2026. The text of the main study measures changed. Edits to capitalization, punctuation or spacing alone are left out. Newest first.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Incidence of adverse events. After: Measure: Number of Subjects Experiencing Any Adverse Event.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Minimal residual disease negativity rate. After: Measure: Minimal Residual Disease Negative CR Rate.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: The frequency and severity of treatment emergent adverse events (TEAEs), discontinuations due to adverse events (AEs), and laboratory abnormalities after dosing with AB-729 plus Peg-IFNα-2a. After: Measure: The Frequency and Severity of Treatment Emergent Adverse Events (TEAEs), Discontinuations Due to AEs and Lab Abnormalities After Dosing With AB-729 Plus Peg-IFNα-2a.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Change From Baseline in Angina Frequency Measure: Change From Baseline in CCS Angina Class Measure: Change From Baseline in Total Exercise Time Measure: Change From Baseline in Health-related Quality of Life (HRQoL). After: Measure: Change From Baseline in Number of Angina Attacks Per Week Measure: Change From Baseline in CCS Angina Class Measure: Change From Baseline in Total Exercise Time Measure: Change From Baseline in Health-related Quality of Life (HRQoL).
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Number of participants with adverse events (AEs). After: Measure: Number of Subjects With Serious Adverse Events.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Ocular itching evaluated by the Subject.. After: Measure: Subject-Reported Ocular Itching Score Assessed in the Allergy Chamber.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Determine the Objective Response Rate (ORR) following treatment with PRGN-2009 in combination with pembrolizumab or pembrolizumab alone in patients with pembrolizumab-resistant recurrent or metastatic cervical cancer.. After: Measure: Determine the Objective Response Rate (ORR) following treatment with PRGN-2009 in combination with pembrolizumab in patients with pembrolizumab-resistant recurrent or metastatic cervical cancer..
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: All-cause Mortality. After: Measure: Composite of All-cause Mortality, Requirement for ICU Admission and/or Ventillatory Support and Cardiovascular Complications.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Change from baseline in daily average nausea severity scores from the Gastroparesis Core Symptom Daily Diary (GCS-DD). After: Measure: Change From Baseline to Week 12 in the Biweekly Average of Daily Nausea Severity Score Using MMRM Model ITT Population.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Overall survival (OS) Measure: Progression free survival (PFS) as assessed by using RANO-HGG criteria. After: Measure: Overall survival (OS).
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Overall Survival. After: Measure: Overall Survival: All Randomized Population Measure: Overall Survival: Stratified by Histology - Squamous vs. Non-Squamous.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: To evaluate the effect of AMX0035 on residual beta-cell function by monitoring C-peptide levels during a 0-240 minutes mixed-meal tolerance test (MMTT) Measure: To assess the safety and tolerability of AMX0035 administered orally for up to 144 weeks in adult participants with Wolfram syndrome. After: Measure: To evaluate the effect of AMX0035 on residual beta-cell function by monitoring C-peptide levels during a 0-240 minutes mixed-meal tolerance test (MMTT) Measure: To assess the safety and tolerability of AMX0035 administered orally for up to 208 weeks in adult participants with Wolfram syndrome.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Sternal Wound Infection Rate. After: Measure: Sternal Wound Infection (SWI) Rate.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Change From Baseline in the Modified Friedreich Ataxia Rating Scale (mFARS) Score at Week 72. After: Measure: Change From Baseline in the mFARS Score at Week 72 - Modified Intent-to-treat (mITT) Analysis Set Measure: Change From Baseline in the mFARS Score at Week 72 - Intent-to-treat (ITT) Analysis Set.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: MBC substudy: Overall Response Rate (ORR) using RECIST v1.1 based on BICR assessment. After: Measure: Overall Response Rate (ORR) using RECIST v1.1 based on BICR assessment.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Mean % change in BMI. After: Measure: Pivotal Cohort: Mean Percent Change From Baseline in Body Mass Index (BMI) After 52 Weeks on a Therapeutic Regimen.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Overall Survival (OS). After: Measure: Overall Survival (OS) Measure: Progression-Free Survival (PFS).
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Incidence and severity of adverse events (AEs) and laboratory abnormalities (Phase 2) Measure: Efficacy of KYV-101 via Myasthenia Gravis Activities of Daily Living (MG-ADL) change from baseline (Phase 2) Measure: Efficacy of KYV-101 via Myasthenia Gravis Activities of Daily Living (MG-ADL) change from baseline for KYV-101 Treatment Arm to Standard of Care Arm (Phase 3) Measure: Efficacy of KYV-101 via Quantitative Myasthenia Gravis (QMG) change from baseline for KYV-101 Treatment arm to Standard of Care arm. After: Measure: Incidence and severity of adverse events (AEs) and laboratory abnormalities (Phase 2) Measure: Efficacy of KYV-101 via Myasthenia Gravis Activities of Daily Living (MG-ADL) change from baseline (Phase 2) Measure: Efficacy of KYV-101 via Myasthenia Gravis Activities of Daily Living (MG-ADL) change from baseline for KYV-101 Treatment arm to Standard of Care arm (Phase 3) Measure: Efficacy of KYV-101 via Quantitative Myasthenia Gravis (QMG) change from baseline for KYV-101 Treatment arm to Standard of Care arm (Phase 3).
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: To evaluate the efficacy of leronlimab in combination with trifluridine and tipiracil + bevacizumab in participants with CCR5+, refractory, MSS, mCRC.. After: Measure: The efficacy of leronlimab in combination with trifluridine and tipiracil + bevacizumab in participants with relapsed, refractory, MSS, mCRC..
27 in April 2026. Primary completion date moved later while its type (estimated or actual) stayed the same. Largest move first.
Before: 31 Dec 2024. After: 31 Dec 2027.
Before: 30 Sep 2027. After: 28 Feb 2030.
Before: 31 Oct 2023. After: 8 Jan 2026.
Before: 30 May 2026. After: 30 Sep 2027.
Before: 1 Jan 2026. After: 1 Jan 2027.
NCT06757010 · BioVie Inc. (BIVI)
Before: 1 Dec 2025. After: 1 May 2026.
Before: 1 Feb 2026. After: 27 Apr 2026.
Before: 17 Jan 2023. After: 22 Mar 2023.
Before: Oct 2026. After: Mar 2027.
Before: Aug 2026. After: Mar 2027.
Before: Mar 2026. After: Mar 2028.
Before: Nov 2026. After: Nov 2027.
Before: Mar 2025. After: Dec 2027.
Before: Jul 2027. After: 31 Dec 2028.
Before: Nov 2026. After: Mar 2027.
Before: Oct 2024. After: 31 Dec 2027.
Before: Nov 2026. After: Jan 2029.
Before: Aug 2026. After: Jun 2028.
Before: Feb 2026. After: Jun 2026.
Before: 30 Mar 2026. After: Aug 2026.
Before: Jul 2028. After: Apr 2033.
Before: Mar 2026. After: Mar 2027.
Before: Nov 2026. After: Nov 2027.
Before: Feb 2026. After: May 2026.
Before: Jun 2027. After: Dec 2027.
Showing 25 of 27. Browse all tracked trials to open the rest.
2 in April 2026. Primary completion date moved earlier while its type stayed the same. Largest move first.
Before: 30 Jan 2028. After: 11 Nov 2026.
Before: Oct 2026. After: Sep 2026.
25 in April 2026. The participant count changed. Planned and actual counts are shown as recorded. Newest first.
Before: 150 participants (planned). After: 168 participants (actual).
Before: 67 participants (actual). After: 66 participants (actual).
Before: 110 participants (planned). After: 139 participants (actual).
NCT06745908 · ImmunityBio, Inc. (IBRX)
Before: 460 participants (planned). After: 507 participants (planned).
Before: 501 participants (actual). After: 500 participants (actual).
Before: 56 participants (planned). After: 59 participants (actual).
Before: 46 participants (planned). After: 24 participants (planned).
Before: 60 participants (actual). After: 63 participants (actual).
Before: 35 participants (planned). After: 60 participants (planned).
Before: 250 participants (planned). After: 253 participants (actual).
Before: 450 participants (planned). After: 510 participants (planned).
Before: 50 participants (planned). After: 60 participants (planned).
Before: 210 participants (planned). After: 252 participants (actual).
Before: 1538 participants (planned). After: 102 participants (actual).
Before: 700 participants (planned). After: 664 participants (actual).
Before: 150 participants (planned). After: 183 participants (actual).
Before: 840 participants (planned). After: 862 participants (actual).
Before: 840 participants (planned). After: 912 participants (actual).
Before: 138 participants (planned). After: 194 participants (planned).
Before: 20 participants (planned). After: 8 participants (actual).
Before: 80 participants (planned). After: 120 participants (planned).
Before: 120 participants (planned). After: 143 participants (actual).
Before: 351 participants (planned). After: 252 participants (planned).
Before: 30 participants (planned). After: 33 participants (actual).
Before: 436 participants (planned). After: 396 participants (actual).
43 in April 2026. Any other change of recruitment status, such as recruiting to completed. Newest first.
Before: Active not recruiting. After: Completed.
Before: Active not recruiting. After: Completed.
Before: Active not recruiting. After: Completed.
Before: Not yet recruiting. After: Recruiting.
Before: Active not recruiting. After: Recruiting.
Before: Active not recruiting. After: Completed.
NCT06757010 · BioVie Inc. (BIVI)
Before: Recruiting. After: Active not recruiting.
Before: Not yet recruiting. After: Recruiting.
Before: Active not recruiting. After: Completed.
Before: Recruiting. After: Active not recruiting.
Before: Recruiting. After: Active not recruiting.
Before: Not yet recruiting. After: Recruiting.
Before: Not yet recruiting. After: Recruiting.
Before: Not yet recruiting. After: Recruiting.
Before: Not yet recruiting. After: Recruiting.
Before: Active not recruiting. After: Completed.
Before: Not yet recruiting. After: Recruiting.
Before: Recruiting. After: Active not recruiting.
Before: Not yet recruiting. After: Recruiting.
Before: Active not recruiting. After: Completed.
Before: Active not recruiting. After: Completed.
Before: Active not recruiting. After: Recruiting.
Before: Not yet recruiting. After: Recruiting.
Before: Recruiting. After: Completed.
Before: Not yet recruiting. After: Enrolling by invitation.
Showing 25 of 43. Browse all tracked trials to open the rest.
TrialRedline, “Clinical trial registry changes: April 2026”. https://trialredline.com/reports/2026-04
Based on public ClinicalTrials.gov record history. How we collect and check the data